Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

hnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Research and Markets ( ... "Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) ... Stem cell research and experimentation have been ... stem cells have the unique ability to divide ... allows them to differentiate into a wide variety ...
(Date:4/21/2015)... 21, 2015  Scientists from the J. Craig ... published a paper today outlining new synthetic biology ... diatoms. The researchers, led by first author ... Philip Weyman , Ph.D., conclude that these new ... diatom genetics and thus facilitate advances in engineering ...
(Date:4/21/2015)... , April 21, 2015 Ampio Pharmaceuticals, ... a scheduled investor call on Thursday, April 23, 4:30 ... the instructions as follows: Investor call ... number: (844) 789-4877 International toll number: (925) 418-7845 Participant ... advance to Tina Amirkiai , tina.amirkiai@fleishman.com . ...
(Date:4/21/2015)... Mass. , April 21, 2015 /PRNewswire/ ... developing transformative pharmaceutical products for subcutaneous delivery, ... pivotal trial of its investigational proprietary drug ... of edema associated with congestive heart failure. ... scPharmaceuticals is developing a proprietary patch pump.  ...
Breaking Biology Technology:Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3
... Massachusetts, June 26 ,Oridion Systems Ltd. - ... manufacturer of innovative capnography monitoring solutions, announced,that ... from IMDA, the,association of medical specialty sales ... the Company,s achievements in market development,and support ...
... /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin Board: ... firm specializing in the manufacture,research, development, ... announced it signed a one-year contract ... to supply probiotics for Lijia,s,probiotics-based dietary ...
... Congress by sepsis thought ... ... Inc.,(TSX: SDI) today announced the presentation of data that demonstrates the,combined ... diagnostic for the measurement of endotoxin, to,identify patients with elevated endotoxin ...
Cached Biology Technology:Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 2Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 3Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributor's Association 4China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company 2China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company 3Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics 2
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Seawater is a complex, dynamic mixture of dissolved ... best efforts, presents difficulties in measuring its potential ... itself, the calculations scientists employ to measure seawater ... the years as research techniques and instrumentation continues ...
... Baltimore, MDDouglas E. Koshland, staff scientist at Carnegie,s ... 72 Fellows by the American Academy of Microbiology. ... peer-review process, based on their records of scientific ... , Using the simple, single-celled yeast Saccharomyces ...
... Researchers have found evidence that a direct interaction between ... risk of developing multiple sclerosis (MS). The research, published ... Genetics , suggests that vitamin D deficiency during pregnancy ... the offspring developing MS later in life. MS ...
Cached Biology News:New equation of state of seawater 2New equation of state of seawater 3Carnegie's Doug Koshland elected Fellow of the American Academy of Microbiology 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 3
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Request Info...
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Biology Products: